DPT vaccine

The DPT vaccine is a combination vaccine used to protect humans from three specific infectious diseases. These diseases are diphtheria, tetanus, and pertussis, which is also known as whooping cough. Diphtheria can cause a thick, grey pseudomembrane to grow over a person's tonsils.

Tetanus is often referred to as lockjaw. By combining these three protections into one shot, medical professionals can provide broad immunity efficiently. This class of vaccine is vital for maintaining public health and preventing widespread outbreaks.

To understand how it works, we must look at the mechanism of a toxoid. A toxoid is an inactivated toxin produced by a pathogen. Instead of targeting the germ itself, the vaccine teaches the immune system to recognize and fight the toxin the germ creates. The DPT vaccine includes diphtheria and tetanus toxoids. For the pertussis component, it uses either killed whole cells of the bacterium or specific pertussis antigens. Because these vaccines do not contain live pathogens, they do not pose a known risk of causing the disease in immune-compromised populations. This makes the vaccine a safe and highly targeted tool for the immune system.

There are two main types of these combination vaccines categorized by their pertussis component. The first is DTwP, where the lowercase "w" stands for whole-cell inactivated pertussis. This version uses the entire killed bacterium to trigger an immune response. The second is DTaP, where the lowercase "a" stands for acellular. An acellular vaccine uses only selected antigens, or specific parts, of the pertussis pathogen. While DTaP is associated with fewer side effects, research suggests DTwP may be more effective. This is because the narrower antigen base of DTaP might be less effective against certain current pathogen strains.

History shows that these vaccines have fundamentally changed human health. The DTP vaccine was first licensed in 1949. Following its introduction, there was an extensive decline in the incidence of pertussis. In the United States, the whole-cell DPT vaccine was the standard until 1996. At that time, the acellular DTaP vaccine was licensed for use. In June 2005, the Tdap vaccine was licensed for use in adolescents and adults. This version uses a smaller concentration of diphtheria toxoids and pertussis antigens.

Vaccination data provides a clear picture of how these tools are used globally. In 2016, the CDC reported that 80.4% of children in the United States had received four or more DTaP vaccinations by age two. For older children, the vaccination rate for those aged 13–17 receiving Tdap was 90.2% in 2019. However, only 43.6% of adults over age 18 have received a Tdap shot in the last ten years. Globally, the World Health Organization estimates that 89% of people have received at least one dose of DTP. They also estimate that 84% of people have completed the recommended three-dose primary series, known as DTP3.

Different versions of the vaccine serve specific age groups and needs. The Td vaccine is used for children over age seven and adults, often as a booster every ten years. The DT vaccine is reserved for children under seven who cannot receive the pertussis component due to medical reasons. For pregnant women, the Tdap vaccine is recommended to reduce the risk of pertussis in infants. In the United States, the Advisory Committee on Immunization Practices recommended Tdap during every pregnancy starting in 2012. Some countries also use pentavalent vaccines, which combine DTP with vaccines for hepatitis B and Haemophilus influenzae type B.

While these vaccines are safe, they can cause side effects. Common reactions to DTaP include soreness at the injection site, fever, irritability, and vomiting. These are usually mild and last only one to three days. More serious but rare reactions can include seizures or high fever. For Tdap, side effects may include headache, tiredness, or stomach aches. In pregnant women, research has noted an increased risk of chorioamnionitis, which is a placental infection. However, studies have not found an increase in preterm births or other serious pregnancy complications from the vaccine. The primary risk remains the diseases themselves, as a 2009 study noted that the greatest danger to unvaccinated children is the contraction of the diseases the vaccine prevents.